Back to search
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials you may qualify forBackground: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the c…
To learn if asciminib can help to control CML. The safety and effects of this drug will also be studied.
This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in trea…
A multi-centre phase II trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirol…
The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs. Full extrap…
The aim of this study is to support development of asciminib in the pediatric population (1 to \< 18 years) with Ph+ CML-CP. The study will evaluate the efficac…
Natural killer (NK) cells are white blood cells that have a limited ability to kill cancer cells. This ability might be enhanced if they are given 24 hours afte…
This phase II trial studies how stopping tyrosine kinase inhibitors will affect treatment-free remission in patients with chronic myeloid leukemia in chronic ph…
The goal of this clinical research study is to find out if treatment with a combination of dasatinib plus ropeginterferon can help to control CML-CP. The safety…